Annals of Hematology

, Volume 96, Issue 5, pp 805–815 | Cite as

Improved prognostic stratification power of CIBMTR risk score with the addition of absolute lymphocyte and eosinophil counts at the onset of chronic GVHD

  • Joon Ho Moon
  • Nada Hamad
  • Sang Kyun Sohn
  • Jieun Uhm
  • Naheed Alam
  • Vikas Gupta
  • Jeffrey H. Lipton
  • Hans A. Messner
  • Matthew Seftel
  • John Kuruvilla
  • Dennis (Dong Hwan) Kim
Original Article


The CIBMTR chronic graft-versus-host disease (cGVHD) risk score can be refined and improved for better prognostic stratification. Three hundred and seven consecutive patients diagnosed with cGVHD by the NIH consensus criteria were retrospectively reviewed and had the CIBMTR risk score applied and analyzed. The CIBMTR risk score was successfully validated in our cohort (n = 307). The 3-year overall survival (OS) rates in each risk group (RG) were 82.5 ± 11.3% (RG1), 79.4 ± 3.0% (RG2), 71.8 ± 6.3% (RG3), and 27.3 ± 13.4% (RG4). A significantly lower OS rate and higher non-relapse mortality (NRM) were noted in RG4 compared to the other RGs. However, there were no differences in OS or NRM among RG1 to 3. To improve prognostic stratification power of the CIBMTR risk score, we incorporated the absolute lymphocyte (ALC) and eosinophil count (EC) at time of cGVHD into the CIBMTR risk score. Lower ALC (<1.0 × 109/L, HR 1.94, p = 0.014) and lower EC (<0.5 × 109/L, HR 3.27, p = 0.014) were confirmed as adverse risk factors for OS. Patients were stratified into four revised risk groups (rRG). The 3-year OS rates were 93.3 ± 6.4% (rRG1, score 0–3), 84.9 ± 3.4% (rRG2, score 4–6), 70.9 ± 4.4% (rRG3, score 7–9), and 32.0 ± 1.1% (rRG4, score ≥ 10) (p < 0.001). The 3-year NRM rates were 0.0% (rRG1), 6.7 ± 0.4% (rRG2), 18.4 ± 0.7% (rRG3), and 57.7 ± 5.1% (rRG4) (p < 0.001). The revised CIBMTR risk score was superior to the original CIBMTR risk score for OS (p < 0.001). The revised CIBMTR risk score including ALC and EC at the onset of cGVHD improved the prognostic stratification power of the CIBMTR risk score for long-term outcomes.


Allogeneic stem cell transplantation Graft-versus-host disease CIBMTR risk score Absolute lymphocyte count Eosinophil count 



J.H.M.: provided the acquisition of data, analysis and interpretation of data, drafting the article, revised it critically for important intellectual content; S.K.S.: revised the article critically for important intellectual content; N.H. and J.U.: supplied the acquisition of data, revision of manuscript and approved final version of manuscript; N.A., V.G., J.L., H.M., M.S. and J.K.: revised the article critically for important intellectual content and approved final version of manuscript; D.K.: provided the conception and design of the study, revised the article critically for important intellectual content, approved final version of manuscript and worked as senior author.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Supplementary material

277_2017_2939_MOESM1_ESM.doc (36 kb)
ESM 1 (DOC 35 kb)
277_2017_2939_MOESM2_ESM.doc (84 kb)
ESM 2 (DOC 84 kb)
277_2017_2939_MOESM3_ESM.doc (81 kb)
ESM 3 (DOC 81 kb)
277_2017_2939_MOESM4_ESM.doc (208 kb)
ESM 4 (DOC 208 kb)


  1. 1.
    Baird K, Steinberg SM, Grkovic L, Pulanic D, Cowen EW, Mitchell SA, Williams KM, Datiles MB, Bishop R, Bassim CW, Mays JW, Edwards D, Cole K, Avila DN, Taylor T, Urban A, Joe GO, Comis LE, Berger A, Stratton P, Zhang D, Shelhamer JH, Gea-Banacloche JC, Sportes C, Fowler DH, Gress RE, Pavletic SZ (2013) National Institutes of Health chronic graft-versus-host disease staging in severely affected patients: organ and global scoring correlate with established indicators of disease severity and prognosis. Biol Blood Marrow Transplant 19(4):632–639CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Ayuk F, Veit R, Zabelina T, Bussmann L, Christopeit M, Alchalby H, Wolschke C, Lellek H, Bacher U, Zander AR, Kroger N (2015) Prognostic factors for survival of patients with newly diagnosed chronic GVHD according to NIH criteria. Ann Hematol 94(10):1727–1732CrossRefPubMedGoogle Scholar
  3. 3.
    Nakamae H, Storer B, Sandmaier BM, Maloney DG, Davis C, Corey L, Storb R, Boeckh M (2011) Cytopenias after day 28 in allogeneic hematopoietic cell transplantation: impact of recipient/donor factors, transplant conditions and myelotoxic drugs. Haematologica 96(12):1838–1845CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Kuzmina Z, Eder S, Bohm A, Pernicka E, Vormittag L, Kalhs P, Petkov V, Stary G, Nepp J, Knobler R, Just U, Krenn K, Worel N, Greinix HT (2012) Significantly worse survival of patients with NIH-defined chronic graft-versus-host disease and thrombocytopenia or progressive onset type: results of a prospective study. Leukemia 26(4):746–756CrossRefPubMedGoogle Scholar
  5. 5.
    Vaughn JE, Gooley T, Maziarz RT, Pulsipher MA, Bhatia S, Maloney DG, Sandmaier BM, Flowers ME, Storb R, Sorror ML (2015) Pre-transplant comorbidity burden and post-transplant chronic graft-versus-host disease. Br J Haematol 171(3):411–416CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Castilla-Llorente C, Martin PJ, McDonald GB, Storer BE, Appelbaum FR, Deeg HJ, Mielcarek M, Shulman H, Storb R, Nash RA (2014) Prognostic factors and outcomes of severe gastrointestinal GVHD after allogeneic hematopoietic cell transplantation. Bone Marrow Transplant 49(7):966–971CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Ayuk F, Bussmann L, Zabelina T, Veit R, Alchalby H, Wolschke C, Lellek H, Bacher U, Zander AR, Kroger N (2014) Serum albumin level predicts survival of patients with gastrointestinal acute graft-versus-host disease after allogeneic stem cell transplantation. Ann Hematol 93(5):855–861CrossRefPubMedGoogle Scholar
  8. 8.
    Martires KJ, Baird K, Steinberg SM, Grkovic L, Joe GO, Williams KM, Mitchell SA, Datiles M, Hakim FT, Pavletic SZ, Cowen EW (2011) Sclerotic-type chronic GVHD of the skin: clinical risk factors, laboratory markers, and burden of disease. Blood 118(15):4250–4257CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Ruutu T, Juvonen E, Remberger M, Remes K, Volin L, Mattsson J, Nihtinen A, Hagglund H, Ringden O (2014) Improved survival with ursodeoxycholic acid prophylaxis in allogeneic stem cell transplantation: long-term follow-up of a randomized study. Biol Blood Marrow Transplant 20(1):135–138CrossRefPubMedGoogle Scholar
  10. 10.
    Verneris MR, Lee SJ, Ahn KW, Wang HL, Battiwalla M, Inamoto Y, Fernandez-Vina MA, Gajewski J, Pidala J, Munker R, Aljurf M, Saber W, Spellman S, Koreth J (2015) HLA mismatch is associated with worse outcomes after unrelated donor reduced-intensity conditioning hematopoietic cell transplantation: an analysis from the Center for International Blood and Marrow Transplant Research. Biol Blood Marrow Transplant 21(10):1783–1789CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Michelis FV, Messner HA, Atenafu EG, McGillis L, Lambie A, Uhm J, Alam N, Seftel MD, Gupta V, Kuruvilla J, Lipton JH, Kim DD (2015) Patient age, remission status and HCT-CI in a combined score are prognostic for patients with AML undergoing allogeneic hematopoietic cell transplantation in CR1 and CR2. Bone Marrow Transplant 50(11):1405–1410CrossRefPubMedGoogle Scholar
  12. 12.
    Arai Y, Kondo T, Yamazaki H, Takenaka K, Sugita J, Kobayashi T, Ozawa Y, Uchida N, Iwato K, Kobayashi N, Takahashi Y, Ishiyama K, Fukuda T, Ichinohe T, Atsuta Y, Mori T, Teshima T (2016) Allogeneic unrelated bone marrow transplantation from older donors results in worse prognosis in recipients with aplastic anemia. Haematologica 101(5):644–652CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Rezvani AR, Storer BE, Guthrie KA, Schoch HG, Maloney DG, Sandmaier BM, Storb R (2015) Impact of donor age on outcome after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 21(1):105–112CrossRefPubMedGoogle Scholar
  14. 14.
    Levine JE, Logan B, Wu J, Alousi AM, Ho V, Bolanos-Meade J, Weisdorf D (2010) Graft-versus-host disease treatment: predictors of survival. Biol Blood Marrow Transplant 16(12):1693–1699CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    MacMillan ML, Robin M, Harris AC, DeFor TE, Martin PJ, Alousi A, Ho VT, Bolanos-Meade J, Ferrara JL, Jones R, Arora M, Blazar BR, Holtan SG, Jacobsohn D, Pasquini M, Socie G, Antin JH, Levine JE, Weisdorf DJ (2015) A refined risk score for acute graft-versus-host disease that predicts response to initial therapy, survival, and transplant-related mortality. Biol Blood Marrow Transplant 21(4):761–767CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Arora M, Klein JP, Weisdorf DJ, Hassebroek A, Flowers ME, Cutler CS, Urbano-Ispizua A, Antin JH, Bolwell BJ, Boyiadzis M, Cahn JY, Cairo MS, Isola L, Jacobsohn DA, Jagasia M, Klumpp TR, Lee SJ, Petersdorf EW, Santarone S, Gale RP, Schouten HC, Spellman S, Wingard JR, Horowitz MM, Pavletic SZ (2011) Chronic GVHD risk score: a Center for International Blood and Marrow Transplant Research analysis. Blood 117(24):6714–6720CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Inamoto Y, Kim DD, Storer BE, Moon JH, Lipton JH, Kuruvilla J, Martin PJ, Flowers ME (2014) Application of CIBMTR risk score to NIH chronic GVHD at individual centers. Blood 123(3):453–455CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Storek J, Espino G, Dawson MA, Storer B, Flowers ME, Maloney DG (2000) Low B-cell and monocyte counts on day 80 are associated with high infection rates between days 100 and 365 after allogeneic marrow transplantation. Blood 96(9):3290–3293PubMedGoogle Scholar
  19. 19.
    Storek J, Gooley T, Witherspoon RP, Sullivan KM, Storb R (1997) Infectious morbidity in long-term survivors of allogeneic marrow transplantation is associated with low CD4 T cell counts. Am J Hematol 54(2):131–138CrossRefPubMedGoogle Scholar
  20. 20.
    Kumarasamy N, Mahajan AP, Flanigan TP, Hemalatha R, Mayer KH, Carpenter CC, Thyagarajan SP, Solomon S (2002) Total lymphocyte count (TLC) is a useful tool for the timing of opportunistic infection prophylaxis in India and other resource-constrained countries. J Acquir Immune Defic Syndr 31(4):378–383CrossRefPubMedGoogle Scholar
  21. 21.
    Schreibman T, Friedland G (2004) Use of total lymphocyte count for monitoring response to antiretroviral therapy. Clin Infect Dis 38(2):257–262CrossRefPubMedGoogle Scholar
  22. 22.
    Blatt SP, Lucey CR, Butzin CA, Hendrix CW, Lucey DR (1993) Total lymphocyte count as a predictor of absolute CD4+ count and CD4+ percentage in HIV-infected persons. JAMA 269(5):622–626CrossRefPubMedGoogle Scholar
  23. 23.
    Post FA, Wood R, Maartens G (1996) CD4 and total lymphocyte counts as predictors of HIV disease progression. QJM 89(7):505–508CrossRefPubMedGoogle Scholar
  24. 24.
    Kim DH, Popradi G, Xu W, Gupta V, Kuruvilla J, Wright J, Messner HA, Lipton JH (2009) Peripheral blood eosinophilia has a favorable prognostic impact on transplant outcomes after allogeneic peripheral blood stem cell transplantation. Biol Blood Marrow Transplant 15(4):471–482CrossRefPubMedGoogle Scholar
  25. 25.
    Aisa Y, Mori T, Nakazato T, Shimizu T, Yamazaki R, Ikeda Y, Okamoto S (2007) Blood eosinophilia as a marker of favorable outcome after allogeneic stem cell transplantation. Transpl Int 20(9):761–770CrossRefPubMedGoogle Scholar
  26. 26.
    Pond GR, Lipton JH, Messner HA (2006) Long-term survival after blood and marrow transplantation: comparison with an age- and gender-matched normative population. Biol Blood Marrow Transplant 12(4):422–429CrossRefPubMedGoogle Scholar
  27. 27.
    Gupta V, Daly A, Lipton JH, Hasegawa W, Chun K, Kamel-Reid S, Tsang R, Yi QL, Minden M, Messner H, Kiss T (2005) Nonmyeloablative stem cell transplantation for myelodysplastic syndrome or acute myeloid leukemia in patients 60 years or older. Biol Blood Marrow Transplant 11(10):764–772CrossRefPubMedGoogle Scholar
  28. 28.
    Kiss TL, Panzarella T, Messner HA, Meharchand J, Reddy V, Schimmer AD, Lipton JH (2003) Busulfan and cyclophosphamide as a preparative regimen for allogeneic blood and marrow transplantation in patients with non-Hodgkin’s lymphoma. Bone Marrow Transplant 31(2):73–78CrossRefPubMedGoogle Scholar
  29. 29.
    Messner HA (2002) Long-term outcome of allogeneic transplants in acute myeloid leukemia. Leukemia 16(4):751–752CrossRefPubMedGoogle Scholar
  30. 30.
    Kim DH, Jamal N, Saragosa R, Loach D, Wright J, Gupta V, Kuruvilla J, Lipton JH, Minden M, Messner HA (2007) Similar outcomes of cryopreserved allogeneic peripheral stem cell transplants (PBSCT) compared to fresh allografts. Biol Blood Marrow Transplant 13(10):1233–1243CrossRefPubMedGoogle Scholar
  31. 31.
    Kim DH, Messner H, Minden M, Gupta V, Kuruvilla J, Wright J, Lipton J (2008) Factors influencing varicella zoster virus infection after allogeneic peripheral blood stem cell transplantation: low-dose acyclovir prophylaxis and pre-transplant diagnosis of lymphoproliferative disorders. Transpl Infect Dis 10(2):90–98CrossRefPubMedGoogle Scholar
  32. 32.
    Kim DH, Messner H, Minden M, Gupta V, Kuruvilla J, Wright J, Lipton J (2007) Factors influencing varicella zoster virus infection after allogeneic peripheral blood stem cell transplantation: low-dose acyclovir prophylaxis and pre-transplant diagnosis of lymphoproliferative disorders. Transpl Infect Dis 10(2):90–98CrossRefPubMedGoogle Scholar
  33. 33.
    Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J, Thomas ED (1995) 1994 consensus conference on acute GVHD grading. Bone Marrow Transplant 15(6):825–828PubMedGoogle Scholar
  34. 34.
    Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ, Martin P, Chien J, Przepiorka D, Couriel D, Cowen EW, Dinndorf P, Farrell A, Hartzman R, Henslee-Downey J, Jacobsohn D, McDonald G, Mittleman B, Rizzo JD, Robinson M, Schubert M, Schultz K, Shulman H, Turner M, Vogelsang G, Flowers ME (2005) National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 11(12):945–956CrossRefPubMedGoogle Scholar
  35. 35.
    Vigorito AC, Campregher PV, Storer BE, Carpenter PA, Moravec CK, Kiem HP, Fero ML, Warren EH, Lee SJ, Appelbaum FR, Martin PJ, Flowers ME (2009) Evaluation of NIH consensus criteria for classification of late acute and chronic GVHD. Blood 114(3):702–708CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    Heining C, Spyridonidis A, Bernhardt E, Schulte-Monting J, Behringer D, Grullich C, Jakob A, Bertz H, Finke J (2007) Lymphocyte reconstitution following allogeneic hematopoietic stem cell transplantation: a retrospective study including 148 patients. Bone Marrow Transplant 39(10):613–622CrossRefPubMedGoogle Scholar
  37. 37.
    Ahmad I, Labbe AC, Chagnon M, Busque L, Cohen S, Kiss T, Lachance S, Roy DC, Sauvageau G, Roy J (2011) Incidence and prognostic value of eosinophilia in chronic graft-versus-host disease after nonmyeloablative hematopoietic cell transplantation. Biol Blood Marrow Transplant 17(11):1673–1678CrossRefPubMedGoogle Scholar
  38. 38.
    Kanda Y (2013) Investigation of the freely available easy-to-use software ’EZR’ for medical statistics. Bone Marrow Transplant 48(3):452–458CrossRefPubMedGoogle Scholar
  39. 39.
    Weisdorf D, Spellman S, Haagenson M, Horowitz M, Lee S, Anasetti C, Setterholm M, Drexler R, Maiers M, King R, Confer D, Klein J (2008) Classification of HLA-matching for retrospective analysis of unrelated donor transplantation: revised definitions to predict survival. Biol Blood Marrow Transplant 14(7):748–758CrossRefPubMedPubMedCentralGoogle Scholar
  40. 40.
    Shulman HM, Sullivan KM, Weiden PL, McDonald GB, Striker GE, Sale GE, Hackman R, Tsoi MS, Storb R, Thomas ED (1980) Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med 69(2):204–217CrossRefPubMedGoogle Scholar
  41. 41.
    Perez-Simon JA, Encinas C, Silva F, Arcos MJ, Diez-Campelo M, Sanchez-Guijo FM, Colado E, Martin J, Vazquez L, del Canizo C, Caballero D, San Miguel J (2008) Prognostic factors of chronic graft-versus-host disease following allogeneic peripheral blood stem cell transplantation: the national institutes health scale plus the type of onset can predict survival rates and the duration of immunosuppressive therapy. Biol Blood Marrow Transplant 14(10):1163–1171CrossRefPubMedGoogle Scholar
  42. 42.
    Socie G (2011) Chronic GVHD: a new risk score? Blood 117(24):6408–6409CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2017

Authors and Affiliations

  • Joon Ho Moon
    • 1
  • Nada Hamad
    • 2
  • Sang Kyun Sohn
    • 1
  • Jieun Uhm
    • 2
  • Naheed Alam
    • 2
  • Vikas Gupta
    • 2
  • Jeffrey H. Lipton
    • 2
  • Hans A. Messner
    • 2
  • Matthew Seftel
    • 2
  • John Kuruvilla
    • 2
  • Dennis (Dong Hwan) Kim
    • 2
  1. 1.Department of Hematology/OncologyKyungpook National University HospitalDaeguKorea
  2. 2.Allogeneic Blood and Marrow Transplantation Program, Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Department of MedicineUniversity of TorontoTorontoCanada

Personalised recommendations